Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 1993 Dec;13(6):665–675. doi: 10.1007/BF00711565

Biphasic effects of suramin on125I-epidermal growth factor binding to human meningiomas

Keisuke Tsutsumi 1,✉, Naoki Kitagawa 1, Masami Niwa 2, Seiichi Yamaga 1, Humayun Khalid 1, Kohtaro Taniyama 2, Akihiko Himeno 3, Shobu Shibata 1
PMCID: PMC11566941  PMID: 8194082

Abstract

  1. We studied the effects of suramin, a nonspecific growth factor antagonist, on epidermal growth factor (EGF) binding to cell surface receptors in surgically excised human meningiomas, using quantitative receptor autoradiographic methods with radioluminography.

  2. High concentrations (10−4–10−2 M) of suramin inhibited125I-EGF binding to meningioma sections with IC50's of 3.2 ± 0.4 × 10−4 M, whereas lower concentrations (10−5–10−4 M) of the drug significantly enhanced EGF binding to the tumor. Scatchard analysis of EGF binding profile revealed significant increases in binding affinity following incubation in the presence of 5 × 10−5 M suramin, without significant alterations in maximal binding capacity.

  3. The addition of 10−3 M suramin to the incubation buffer rapidly dissociated125I-EGF previously bound to meningioma tissues as a function of time (dissociation half-life,T 1/2 = 12.4 min).

  4. Preincubation in the presence of 5 × 10−5 M suramin resulted in significant increases in the subsequent binding of125I-EGF to meningiomas, compared to findings in the control.

  5. Our data indicate that (a) suramin exerts biphasic effects on EGF binding to the tissue sections of meningiomasin vitro, depending on the concentration of the drug; and (b) low concentrations of suramin enhance the affinity of the EGF receptor in the tumor sections, probably by interacting with the EGF receptor molecule rather than with the EGF peptide.

  6. The functional role of increased EGF receptor affinity in meningioma sections in the presence of lower concentrations of suramin remains to be determined.

Key words: suramin, epidermal growth factor (EGF) receptor, meningioma, quantitative receptor autoradiography, radioluminography

References

  1. Amemiya, Y., and Miyahara, J. (1988). Imaging plate illuminates many fields.Nature33689–90. [DOI] [PubMed] [Google Scholar]
  2. Cardinali, M., Sartor, O., and Robbins, K. C. (1992). Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells.J. Clin. Invest.891242–1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coffey, R. J., Leof, E. B., Shipley, G. D., and Moses, H. L. (1987). Suramin inhibition of growth factor receptor binding and mitogenesity in AKR-2B cells.J. Cell. Physiol.132143–148. [DOI] [PubMed] [Google Scholar]
  4. Foekens, J. A., Sieuwerts, A. M., and Stuurman-Smeets, E. M. J. (1992). Pleiotrophic actions of suramin on the proliferation of human breast-cancer cells in vitro.Int. J. Cancer51439–444. [DOI] [PubMed] [Google Scholar]
  5. Glick, R. P., Untermann, T. G., Van der Woude, M., and Blaydes, L. Z. (1992). Insulin and insulin-like growth factors in central nervous system tumors. Part V. Production of insulin-like growth factors I and IIin vitro.J. Neurosurg.77445–450. [DOI] [PubMed] [Google Scholar]
  6. Hosang, M. (1985). Suramin binds to platelet-derived growth factor and inhibits its biological activity.J. Cell Biochem.29265–273. [DOI] [PubMed] [Google Scholar]
  7. Kurihara, M., Tokunaga, Y., Tsutsumi, K., Kawaguchi, T., Shigematsu, K., Niwa, M., and Mori, K. (1989). Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma.J. Neurosurg.71538–544. [DOI] [PubMed] [Google Scholar]
  8. La Rocca, R. V., Myers, C. E., Stein, C. A., Cooper, M. R., and Uhrich, M. (1990a). Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy.Proc. Am. Soc. Clin. Oncol.91041–1268. [Google Scholar]
  9. La Rocca, R. V., Stein, C. A., Danesi, R., Jamis-Dow, C. A., Weiss, G. H., and Myers, C. E. (1990b). Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxity in vitro, and clinical antitumor effect.J. Clin. Endoclinol. Metab.71497–504. [DOI] [PubMed] [Google Scholar]
  10. La Rocca, R. V., Stein, C. A., and Myers, C. E. (1990c). Suramin: Prototype of a new generation of antitumor compounds.Cancer Cells2106–115. [PubMed] [Google Scholar]
  11. La Rocca, R. V., Cooper, M. R., Uhrich, M., Danesi, R., Walther, M. M., Linehan, W. M., and Myers, C. E. (1991a). Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.Urol. Clin. No. Am.18123–129. [PubMed] [Google Scholar]
  12. La Rocca, R. V., Danesi, R., Cooper, M. R., Jamis-Dow, C. A., Ewing, M., Linehan, M. W., and Myers, C. E. (1991b). Effect of suramin on human prostate cancer cells in vitro.J. Urol.145393–398. [DOI] [PubMed] [Google Scholar]
  13. McPherson, G. A. (1985). Analysis of radioligand binding experiments: A collection of computer program for the IBM PC.J. Pharmacol. Methods14213–228. [DOI] [PubMed] [Google Scholar]
  14. Middaugh, C. R., Mack, H., Burke, C. J., Volkin, D. B., Dabora, J. M., Tsai, P. K., Bruner, M. W., Ryan, J. A., and Marfia, K. E. (1992). Nature of the interaction of growth factors with suramin.Biochemistry319016–9024. [DOI] [PubMed] [Google Scholar]
  15. Motzer, R. J., Nanus, D. M., O'Moore, P., Scher, H. I., Bajorin, D. F., Reuter, V., Tong, W. P., Iversen, J., Louison, C., Albino, A. P., and Bosl, G. J. (1992). Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression.Cancer Res.525775–5779. [PubMed] [Google Scholar]
  16. Munson, P. J., and Rodbard, D. (1980). LIGAND: A versatile computerized approach for characterization of ligand-binding systems.Anal. Biochem.107220–239. [DOI] [PubMed] [Google Scholar]
  17. Niwa, M., Kawaguchi, T., Himeno, A., Fujimoto, M., Kurihara, M., Yamashita, K., Kataoka, Y., Shigematsu, K., and Taniyama, K. (1992). Specific binding sites for125I-endothelin-1 in the porcine and human spinal cord.Eur. J. Pharmacol. Mol. Pharmacol. Sect.225281–289. [DOI] [PubMed] [Google Scholar]
  18. Olivier, S., Formento, P., Fischel, J. L., Etienne, M. C., and Milano, G. (1990). Epidermal growth factor receptor expression and suramin cytotoxity in vitro.Eur. J. Cancer26867–871. [DOI] [PubMed] [Google Scholar]
  19. Pollak, M., and Richard, M. (1990). Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells.J. Natl. Cancer Inst.821349–1352. [DOI] [PubMed] [Google Scholar]
  20. Ravera, F., Miglietta, L., Pirani, P., Ferrini, S., and Favoni, R. E. (1993). Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: Potentially related events.Eur. J. Cancer29A225–230. [DOI] [PubMed] [Google Scholar]
  21. Sato, T., Niwa, M., Himeno, A., Tsutsumi, K., and Amemiya, T. (1993). Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: Quantitation with radioluminography.Cell. Mol. Neurobiol.13233–245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Takahashi, J. A., Hori, H., Fukumoto, M., Igarashi, K., Jaye, M., Oda, Y., Kikuchi, H., and Hatanaka, M. (1990). Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues.Proc. Natl. Acad. Sci. USA875710–5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tsutsumi, K., and Saavedra, J. M. (1992). Heterogeneity of angiotensin II AT2 receptors in the rat brain.Mol. Pharmacol.41290–297. [PubMed] [Google Scholar]
  24. Tsutsumi, K., Kitagawa, N., Niwa, M., Himeno, A., Taniyama, K., and Shibata, S. (1993). Suramin interferes with125I-insulin-like growth factor I binding to human meningiomas and inhibits proliferation of meningioma cells.J. Neurosurg. (in press). [DOI] [PubMed]
  25. Weisman, A. S., Villemura, J. G., and Kelly, P. A. (1986). Regulation of DNA synthesis and growth of cells derived from primary human meningiomas.Cancer Res.462545–2550. [PubMed] [Google Scholar]
  26. Williams, L. T., Tremble, P. M., Lavin, M. F., and Sunday, M. E. (1984). Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-liking studies.J. Biol. Chem.2595287–5294. [PubMed] [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES